A Phase II Study of Epacadostat and Pembrolizumab in Patients with Imatinib-Refractory Advanced Gastrointestinal Stromal Tumors

Protocol: 
AAAR1581
Phase: 
II

A Phase II Study of Epacadostat and Pembrolizumab in Patients with Imatinib-Refractory Advanced Gastrointestinal Stromal Tumors

Are you Eligible? (Inclusion Criteria)

• 18 years or older
• Diagnosed advanced gastrointestinal stromal tumor (GIST), where surgery is
not an option
• Greater than one but no more than 4 prior therapies for metastatic
disease.
• Life expectancy of greater than or equal to three months

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States